EFFECT OF ENVIRONMENT ON CRYSTALLINITY AND CHEMICAL STABILITY IN SOLID-STATE OF GROUND CEPHALOTIN SODIUM DURING STORAGE

OTSUKA1* and NOBUYOSHI KANENIWA

School of Pharmaceutical Sciences, Showa University, Hatanodai 1-5-8, Shinagawa-ku, Tokyo 142, Japan.

¹Present address: Dept. of Pharmaceutical Technology,

Motoyama-Kitamachi 4-19-1, Higashi-Nada, Kobe 658, Japan.

Kobe Women's College of Pharmacy,

• to whom correspondence should to addressed.

ABSTRACT

Effects of environmental conditions on the crystallinity decomposition point (Dp) of ground cephalotin sodium during storage were investigated by X-ray diffraction differential thermal analysis (DTA). The X-ray diffraction peaks of ground products increased after storage at 0% and 75% relative humidity (R.H.), at 35°C. The crystallinity of ground increased at 75% R.H. and 0% R.H., 35°C, but ground product at 0% R.H., -30°C was not changed. Dp measured by DTA of the ground product increased from 189.5°C 197 C after 4 days at 75% R.H., but the Dp of the ground product at 0% R.H., -30°C for 4 days was 190.1°C. Relation between and the crystallinity of ground cefalotin sodium was



straight suggesting that the thermal stability of cefaloting sodium in the solid-state depends on the degree of crystallinity.

INTRODUCTION

Changes of physicochemical properties of pharmaceutical preparations during storage are very important to preformulation scientists, because the properties of drug powders affect their bioavailability through effects on the dissolution rate (F.D.A. Guide line)⁽¹⁾. Grinding is often carried out to paper: the particle size of powders, and to mix drugs, but the products of some pharmaceuticals ground (i.e. lactose, indomethacin, cefixime and cephalexin) were very unstable under condition (2-5). Pikal et al. (6) reported relations between the crystallinity of various kinds of cephalotin sodium obtained by freeze-drying or recrystallization and decomposition rate in the solid-state. They concluded that the chemical stability and crystallinity of cephalotin sodium in the solidstate change depending on the preparation method. еt al., (7) reported the crystallinity determination method for freeze-dried cephalotin bу scanning sodium differential We reported changes of physicochemical properties calorimetry. freeze-drying and grinding of cephalexin(5,8,9), due indomethacin (1989)⁽¹⁰⁾, and phenylbutazone⁽¹¹⁾ during storage under various conditions. In a previous study, we investigated the effect of mechanochemical stress on the crystallinity and chemical stability of cephalotin sodium in the solid-state during In the present study, we investigated the chemical grinding. stability of ground cefalotin sodium during storage and relations decomposition point and crystallinity of between cephalotin sodium.



MATERIALS AND METHODS

Materials

Bulk powder of crystalline cephalotin sodium (Lot. No. ERON-1300; Meiji Seika Ltd.) was used. A sample of cephalotin sodium powder (10 g) was ground in an agate centrifugal ball mill (Fritsch Co. Ltd.) for 10 h with a capacity of 350 ml, described previously (12).

Powder X-ray diffraction analysis

Powder X-ray diffraction was measured at room temperature with a type JDX 7E diffractometer (Nihon Denshi Co., Ltd.). measurement conditions were: target, Cu; filter, Ni; voltage, kV; current, 10 mA; time constant, 2 sec; measured from 20=3 to $20 = 40^{\circ}$.

<u>Determination</u> of crystallinity

Crystallinity was estimated by Hermans' method (13). The degree of crystallinity of an intact sample was regarded as and estimated from the X-ray diffraction profiles as reported previously (12).


Thermal analysis

Differential thermal analysis (DTA) curves were measured with a type DT-20 DTA instrument (Shimadzu Seisakusho Co. Ltd.). measurement conditions were: sample weight, 3 mg for DTA; heating 10°C/min; N₂ gas flow, 30 ml/min; sample cell, aluminium crimp cell.

Storage conditions

The ground products were stored in desiccator containing (0% relative humidity (R.H.)) at 0°C and 35°C, and NaCl saturated solution (75% R.H.) at 35°C.





Change of X-ray diffraction profiles of ground cephalotin sodium during storage (a), Intact powder; (b), the fresh product ground for 10 h; (c), after storage the ground product at 75% R.H. 35 C for 4 days.

RESULTS

crystallinity of cephalotin sodium during storage Change <u>in</u> period

1 shows the change of X-ray diffraction profiles ground cephalotin sodium during storage. The X-ray diffraction cephalotin sodium increased with increasing peaks of ground storage time, suggesting that crystal growth in the occurred in the ground cephalotin sodium bulk.






Fig. 2 Effects of storage conditions on the crystallinity of ground cephalotin sodium 0% R.H. at 35°C; ⋈, 0% R.H. at -30°C; □, 75% R.H. at 35°C.

Figure shows change in crystallinity of the cephalotin sodium during storage at 0% and 75% R.H., 35°C and -When stored at 75% R.H., 35°C the crystallinity of ground increased very rapidly, initially, to plateau However, the crystallinity of ground product at 35°C was almost linear, and increased very slow than that at R.H., 35°C, and that of ground product at 0% R.H., -30°C was changed.

3 shows changes of the decomposition point ground cephalotin sodium during storage. The Dp was estimated from DTA curves by extrapolation of the exothermic peak. The Dp






Fig. 3 Effects of storage conditions on the decomposition point (Dp) of ground cephalotin sodium Δ, 0% R.H. at 35°C; ⋈, 0% R.H. at -30°C; □, 75% R.H. at 35°C.

of the intact cephalotin sodium did not changed after storage The Dp of 35°C for 2 weeks. 75% R.H.. the ground product increased to about 8°C, after storage for 1 day at 75% R.H., 35° C. However, the Dp of the ground sample increased only storage at 0% R.H., 35°C for 4 days, and the Dp storage at 0% R.H., -30°C for 4 days. changed after The adsorbed water amount of the intact and ground samples were than 0.1%, respectively, after storage at 75% R.H., 35°C for days, as shown in previously (12).



Relations between decomposition point and crystallinity of ground cephalotin sodium

Figure shows the relation between the Dp and crystallinity of the freshly ground samples reported in previous study $^{(12)}$, and of samples ground and stored at 0%and 75% R.H., 35°C. The relations fall on a straight line, which suggests that the thermal stability of cephalotin sodium in solid-state depended on the degree of crystallinity.

DISCUSSION

Effect of R.H. on the of crystallinity and the Dp of ground cephalotin sodium during storage

We reported that the Dp of ground cephalotin sodium $^{(12)}$ fell with increase of grinding time, because the thermal stability of sodium the solid-state depended cephalotin in the on Pikal et al. (6) reported crystallinity of the bulk solid. the relation between the chemical stability of freeze-dried sodium and the crystallinity in an cephalotin isothermal Suzuki et al., (7) reported that three kinds of environment. solid-state for freeze-dried cephalotin sodium were amorphus, and crystalline by differential quasi-crystalline scanning The amorphus, quasi-crystalline and crystalline calorimetry. freeze-dried cephalotin sodium had the decomposition points 140°C, 175°C and 195°C, respectively, and they concluded that the crystallinity of freeze-dried cephalotin sodium affected on The thermal stability of freeze-dried decomposition point. ground cephalexin, an antibiotic with a B-lactam ring structure, decreased with decrease in crystallinity (5,9). present study, the Dp of intact cephalotin sodium was not changed after storage at 75% R.H., 35°C for 2 weeks, but the Dp of ground cephalotin sodium after storage at 0% and 75% R.H., 35°C for






Fig. Relation between the decomposition point (Dp) and crystallinity of ground cephalotin sodium □, at 75% R.H., 35°C; after storage at 0% R.H., 35°C; Fresh ground cephalotin sodium.

Increased with Increased storage (Fig. 3), because the days crystallinity of ground sample increased during storage. suggests that part of the noncrystalline solid of ground cephalotin sodium recrystallized in the solid-state. The recrystallization of ground cephalotin sodium at 75%, than that at 0% R.H., 35°C, since the recrystallization process was affected by the environment (Fig. 2). At 75% R.H., the noncrystalline solid of cephalotin sodium adsorbed water, as reported about freeze-dried cephalexin in a $study^{(9)}$, so the recrystallization accelerated by the presence of water.



 (P_2O_5) , -30° C 0n the other hand, at 0% R.H. the recrystallization of ground cephalotin sodium was more slow at 0% R.H., 35°C, and the Dp of the ground product did not change during storage for 2 weeks. This suggests that the recrystallization of the noncrystalline solid of cephalotin sodium was accelerated by the temperature and the adsorbed water. The linear relation (Fig. 4) between the Dp of all ground samples and the crystallinity suggests that the thermal stability of cephalotin sodium is controlled by the degree ground crystallinity.

In the present study, we used different instruments. measurement conditions and sample preparation method from Pikal et al. (6) and Suzuki et al. (7) for estimating of solid stability of cephalotin sodium, but the stability of ground cephalotin sodium was controlled by the crystallinity as almost the same freeze-dried cephalotin sodium(6,7).

CONCLUSION

recrystallization of ground cephalotin sodium was affected by the environmental (R.H. and temperature). Since noncrystalline solid ofcephalotin sodium has hygroscopicity, adsorbed water accelerated the recrystallization of ground cephalotin sodium. The chemical cephalotin sodium in the solid-state depended Its crystallinity because the noncrystalline solid was very at high R.H. and temperature.

ACKNOWLEDGMENTS

authors wish to express their gratitude to Mr. Tetsuo Hayashi for his assistance in the experimental work. gratefully acknowledge the generous gifts of materials from Meiji Seika Co. Ltd.



REFERENCES

- (1)FDA Paper. "Guide line: Manufacturing and Controls for and NDAs", Pharm. Tech. Japan, 1, 835 (1985).
- (2)M. Morita, Y. Nakai, E. Fukuoka and S. Nakajima, Chem. Pharm. Bull., 32, 4076 (1984).
- (3)M. Otsuka and N. Kaneniwa, Chem. Pharm. Bull., 36, (1988).
- S. Kitamura, A. Miyamae, S. Koda and Y. Morimoto, Inter. (4)Pharm., <u>56,</u> 125 (1989).
- M. Otsuka and N. Kaneniwa, Chem. Pharm. Bull., 32, (1984)
- (6) M. J. Pikal, A. L. Lukes, J. E. Lang and K. Gaines, Pharm. Sci., 67, 767 (1978).
- (7)Y. Suzuki, T. Takeda, K. Inazu, T. Sakamoto and H. Yakugaku Zasshi, 109, 388 (1989).
- M. Otsuka and N. Kaneniwa, Chem. Pharm. Bull., 31, (8) (1983).
- M. Otsuka and N. Kaneniwa, Chem. Pharm. Bull., 31, (9) (1983).
- M. Otsuka, T. Matsumoto and N. Kaneniwa, Chem. Pharm. Bull., 34, 1784 (1986).
- T. Matsumoto, J. Ichikawa, N. Kaneniwa and M. Otsuka, Chem. Pharm. Bull., 36, 1074 (1988).
- Otsuka and N. Kaneniwa, Inter. J. Pharm., 1n (12)(1990).
- P. H. Hermans and A. Weidinger, J. Appl. Phys., 491 (13)(1948).

